| __timestamp | Grifols, S.A. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 660772000 | 35942000 |
| Thursday, January 1, 2015 | 736435000 | 40028000 |
| Friday, January 1, 2016 | 775266000 | 45853000 |
| Sunday, January 1, 2017 | 860348000 | 53816000 |
| Monday, January 1, 2018 | 814775000 | 60804000 |
| Tuesday, January 1, 2019 | 942821000 | 77252000 |
| Wednesday, January 1, 2020 | 985616000 | 45736000 |
| Friday, January 1, 2021 | 1061508000 | 50323000 |
| Saturday, January 1, 2022 | 1190423000 | 143526000 |
| Sunday, January 1, 2023 | 1254234000 | 149182000 |
| Monday, January 1, 2024 | 154335000 |
Unleashing insights
In the competitive landscape of the biopharmaceutical industry, operational efficiency is paramount. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Halozyme Therapeutics, Inc. and Grifols, S.A. over the past decade. Grifols, a global leader in plasma-derived medicines, has seen its SG&A expenses grow by approximately 90% from 2014 to 2023, reflecting its expansive global operations. In contrast, Halozyme, a smaller biotech firm, experienced a staggering 315% increase in SG&A expenses during the same period, indicative of its aggressive growth strategy. By 2023, Grifols' SG&A expenses were nearly 8.5 times higher than Halozyme's, underscoring the scale difference between the two. This comparison highlights the diverse strategies companies employ to manage operational costs while striving for market leadership.
AstraZeneca PLC and Grifols, S.A.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Viatris Inc. and Halozyme Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Grifols, S.A.
Halozyme Therapeutics, Inc. vs Grifols, S.A.: Efficiency in Cost of Revenue Explored
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Halozyme Therapeutics, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs Bausch Health Companies Inc.
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Ligand Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Axsome Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Grifols, S.A. or Novavax, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs Amphastar Pharmaceuticals, Inc.